Loading news...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two companies is the best option for those looking for undervalued stocks?
Catalyst Pharmaceuticals (NASDAQ: CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a recent discussion with Barclays life sciences analyst Glen Santangelo. Chief Executive Officer Rich Daly also reviewed early commercial progress for Agamree in Duchenne muscular dystrophy (DMD), provided an update
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Market volatility is reviving value hunts. AL, NESR, CPRX and JBTM stand out with low PEG metrics and solid growth outlooks after passing strict value screens.
Choreo LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 20,895 shares of the biopharmaceutical company's stock, valued at approximately $412,000. Other large investors also recently made changes to
The consensus price target hints at a 43.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals.
Catalyst (CPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BTSG, XP and CPRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2026.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CPRX and XP made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 4, 2026.
ORN, LRCX, GMED, MYRG and CPRX have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2026.
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported fourth-quarter and full-year 2025 results that management said reflected continued revenue growth across its commercial portfolio, led by Firdapse and AGAMREE, and supported by Fycompa despite generic competition. Executives also outlined 2026 revenue guidance and discussed commercial initiatives aimed at expanding patient identification, improving persistence, and deepening penetration in key treatment
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Net Expected to Grow by 20% or More in 2026 Conference Call and Webcast to be Held on February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for fourth quarter and full year 2025 and provided full year 2026 financial guidance.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Catalyst (CPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.